Safe Harbor Statement
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, performance and results of operations, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
This announcement contains translations of certain Renminbi amounts into US dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from Renminbi to US dollars as of and for the first three months of fiscal 2011 were made at the noon buying rate of RMB6.7815 to $1.00 on June 30, 2010 in the City of New York for cable transfers in Renminbi per US dollar as certified for customs purposes by the Federal Reserve Bank of New York. China Cord Blood Corporation makes no representation that the Renminbi or US dollar amounts referred to in this press release could have been or could be converted into US dollars or Renminbi, at any particular rate or at all.
For more information, please contact: China Cord Blood Corporation Ms. Joeling Law Tel: +852-3605-8180 Email: firstname.lastname@example.org ICR, LLC In New York: Ashley M. Ammon or Christine Duan Tel: +1-646-277-1227 In Beijing: Wen Lei Zheng Tel: +86-10-6599-7968 CHINA CORD BLOOD CORPORATION UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended June 30, 2010 and 2009 Three months ended June 30, 2010 2009 US$ RMB RMB (in thousands except per share data) Revenues 10,572 71,696 57,928 Direct costs (2,544) (17,252) (16,256) Gross profit 8,028 54,444 41,672 Operating expenses Research and development (228) (1,543) -- Sales and marketing (1,488) (10,090) (7,041) General and administrative (2,868) (19,456) (11,576) Total operating expenses (4,584) (31,089) (18,617) Operating income 3,444 23,355 23,055 Other income/(expense), net Interest income 361 2,451 1,031 Interest expense (89) (606) (460) Exchange (loss)/gain (35) (237) 113 Write-off of deferred reverse recapitalization costs -- -- (21,566) Others 17 114 293 Total other income/(expense), net 254 1,722 (20,589) Income before income tax 3,698 25,077 2,466 Income tax expense (901) (6,110) (5,773) Net income/(loss) 2,797 18,967 (3,307) Income attributable to noncontrolling interests (204) (1,381) (1,285) Net income/(loss) attributable to shareholders 2,593 17,586 4,592 Net income/(loss) per share: Attributable to ordinary shares -Basic 0.04 0.26 (0.18) -Diluted 0.04 0.26 (0.18) Attributable to redeemable ordinary shares -Basic -- -- 0.22 -Diluted -- -- 0.22 CHINA CORD BLOOD CORPORATION UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS As of June 30 and March 31, 2010 June 30, March 31, 2010 2010 US$ RMB RMB (in thousands except share data) ASSETS Current assets Cash and cash equivalents 47,676 323,315 280,835 Accounts receivable, less allowance for doubtful accounts (June 30, 2010: RMB8,706; March 31, 2010: RMB8,016) 7,948 53,902 61,349 Inventories 1,126 7,635 5,070 Prepaid expenses and other receivables 1,591 10,788 13,137 Deferred tax assets 612 4,151 3,443 Total current assets 58,953 399,791 363,834 Property, plant and equipment, net 36,546 247,836 250,491 Non-current prepayments 1,199 8,128 151,138 Non-current accounts receivable, less allowance for doubtful accounts (June 30, 2010: RMB12,567; March 31, 2010: RMB9,181) 28,517 193,386 176,874 Inventories 4,546 30,830 29,637 Intangible asset, net 3,842 26,054 26,297 Available-for-sale equity securities 5,502 37,313 48,475 Other investment 20,575 139,532 -- Deferred tax assets 83 565 288 Total assets 159,763 1,083,435 1,047,034 LIABILITIES Current liabilities Bank loan 6,636 45,000 45,000 Accounts payable 966 6,549 5,410 Accrued expenses and other payables 3,241 21,976 22,475 Deferred revenue 6,361 43,135 36,074 Amounts due to related parties 436 2,960 2,977 Income tax payable 769 5,217 4,098 Total current liabilities 18,409 124,837 116,034 Deferred revenue 15,214 103,174 93,155 Other non-current liabilities 2,668 18,096 15,978 Deferred tax liabilities 282 1,910 2,259 Total liabilities 36,573 248,017 227,426 CHINA CORD BLOOD CORPORATION UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS As of June 30 and March 31, 2010 ¨C (continued) June 30, March 31, 2010 2010 US$ RMB RMB (in thousands except share data) EQUITY Shareholders' equity Ordinary shares - US$0.0001 par value, 250,000,000 shares authorized, 67,025,096 shares and 66,743,693 shares issued and outstanding as of June 30 and March 31, 2010, respectively 7 46 46 Additional paid-in capital 107,496 728,983 719,329 Accumulated other comprehensive (loss)/income (1,570) (10,642) 2,221 Retained earnings 15,465 104,876 87,290 Total shareholders' equity 121,398 823,263 808,886 Noncontrolling interests 1,792 12,155 10,722 Total equity 123,190 835,418 819,608 Total liabilities and equity 159,763 1,083,435 1,047,034 m/includes/tooltip.css" type="text/css" />Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Earnings Forecasts & Projections, Earnings
HONG KONG, Sept. 10 /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation (NYSE: CO) ("CCBC" or "the Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced unaudited financial results for the first fiscal quarter ended June 30, 2010.
Highlights -- Net revenue increased 23.8% to RMB71.7 million ($10.6 million). -- Fiscal 2011 first quarter new subscriber sign-ups grew 17.3% to 12,180, exceeding the 12,000 mark for the first time. -- Gross profit rose to RMB54.4 million ($8.0 million) and gross margin improved four percentage points to 75.9%. -- Operating income reached RMB23.4 million ($3.4 million). -- RMB17.6 million ($2.6 million) net income attributable to shareholders compared to a net loss of RMB4.6 million in the prior year period. -- Completed the investment in 19.9% equity interest in the Shandong cord blood bank operator in May 2010. Summary - The quarter ended June 30, 2009 and 2010 Three Months Ended June 30, 2010 2009 USD('000) RMB('000) RMB('000) Revenue 10,572 71,696 57,928 Gross Profit 8,028 54,444 41,672 Operating Income 3,444 23,355 23,055 Net Income/(Loss) Attributable to Shareholders 2,593 17,586 (4,592) EPS Attributable to Ordinary Shares - Basic (USD/RMB) 0.04 0.26 (0.18) Revenue Breakdown (%) Processing Fee 79.1% 84.1% Storage Fee 20.9% 15.9% New Subscribers (persons) 12,180 10,381 Accumulated Total Number of Subscribers (persons) 141,492 94,441
"We are very pleased with our solid performance in the first quarter of fiscal 2011," said Ms. Ting Zheng, Chairperson and Chief Executive Officer of China Cord Blood Corporation. "We have started off a new fiscal year with a record number of new subscribers and such continued accelerated growth in our business affirms our belief that fiscal 2011 will be another remarkable year. Our sales force and hospital network continue to expand reflecting our commitment to further market penetration and deepening our market influence. Due to the large size of the Beijing and Guangdong markets, our penetration level seems modest when compared with the growth opportunities available to us."
Ms. Zheng further commented, "The first quarter was also very eventful. In May 2010, we completed our investment in a 19.9% equity interest in Qilu Stem Cell Engineering Company Limited, the exclusive cord blood bank operator in the Shandong province. In July 2010, our ownership stake in Cordlife increased after the completion of its rights issue." Ms. Zheng added, "The cancellation of our management incentive warrant plan further aligns management's interests with those of shareholders. We have also been added to the Russell Global Index at the end of June 2010. All these events not only reflect our dedicated efforts to improve shareholder value as we work toward becoming the most influential cord blood bank operator in China and the Asia Pacific region, but more importantly, pave the way for the Company to seize any opportunities for further expansion and development in the future."
First Quarter 2011 Financial Results
Total revenue in the first quarter increased 23.8% to RMB71.7 million ($10.6 million) from RMB57.9 million compared to the same period last year. This is also the first time that our quarterly new subscriber number exceeded the 12,000 mark reaching 12,180. Fueled by the growth in new subscriber numbers, revenue generated from processing fees increased 16.4% year-over-year to RMB56.7 million ($8.4 million). Revenue from storage fees increased 62.9% year over year to RMB15.0 million ($2.2 million), due to an increase in the total number of subscribers during the quarter. Our total subscriber base as of June 30, 2010 reached 141,492 subscribers, up 49.8% year-over-year.
Gross profit in the first quarter of fiscal 2011 increased to RMB54.4 million ($8.0 million) from RMB41.7 million in the prior year period. Gross margin expanded by four percentage points to 75.9% primarily due to favorable change in revenue mix, economies of scale and further cost savings. Storage fees accounted for 20.9% of the total revenue mix in the first quarter of fiscal 2011, as compared to 15.9% for the first quarter of fiscal 2010.
Sales and marketing expense for the first quarter amounted to RMB10.1 million ($1.5 million). As part of our commitment to continuously expand our sales and marketing platform, we continued to invest in marketing activities and develop new marketing channels. Such activities will aid the establishment of a more comprehensive sales network and enhance public awareness of cord blood stem cell storage services.
General administration expenses for the quarter amounted to RMB19.5 million ($2.9 million). The increase in general administrative expenses reflected the increase of corporate overhead after listing on the NYSE and the rise in legal and professional expenses. Research and development expense amounted to RMB1.5 million ($0.2 million) in the first quarter of fiscal 2011, reflecting our continued efforts to improve profitability and operating efficiency.
Operating income and net income attributable to shareholders in first quarter fiscal 2011 was RMB23.4 million ($3.4 million) and RMB17.6 million ($2.6 million), respectively. Net margin for the first quarter of fiscal 2011 was 24.5%.
Basic earnings per share for first quarter of fiscal 2011 were RMB0.26 ($0.04).
As of June 30, 2010, we had cash and cash equivalents of RMB323.3 million ($47.7 million), compared to RMB280.8 million as of March 31, 2010. As of June 30, 2010, total borrowing was RMB45 million ($6.6 million).
Ms. Zheng concluded, "Our solid track record within our local markets makes us the role-model for others to follow. It also results in tremendous credibility and facilitates our geographical expansion strategy within China. We will continue to strive in achieving substantial financial performance through organic growth and by pursuing strategic relationships in domestic and international markets as demonstrated by our past achievements."
The Company continues to expect the number of new subscribers to exceed 58,000 for the fiscal year 2011, which would translate into at least a 30% increase in net revenue. The management team also expects to have an accumulated total number of at least 187,000 subscribers at the end of fiscal 2011.
The Company will hold a conference call at 8:00 a.m. ET on Friday, September 10, 2010 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question and answer session.
Interested parties may access the audio webcast through the following link: http://phx.corporate-ir.net/playerlink.zhtml?c=206671&s=wm&e=3297686 . A replay of the webcast will be accessible two hours after the presentation and available for three weeks at the same URL link above. Listeners may also access the call by dialing 1-718-354-1231 or 1-866-519-4004, for US callers, or +852-2475-0994, for Hong Kong callers, access code: 94640489.
About China Cord Blood Corporation
China Cord Blood Corporation is the first and largest cord blood banking
operator in China in terms of geographical coverage and is the only cord blood
bank operator with multiple licenses. Under the current PRC government
regulations, only one licensed cord blood bank operator is permitted to
operate in each licensed region and only six licenses have been issued as of
today. China Cord Blood Corporation provides cord blood collection, laboratory
testing, hematopoietic stem cell processing and stem cell sto
|SOURCE China Cord Blood Corporation|
Copyright©2010 PR Newswire.
All rights reserved